Clinical Trial Update: Anlotinib Combined With mXELIRI as Second-line Treatment of Advanced Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update investigates anlotinib combined with mXELIRI as second-line therapy for advanced colorectal cancer in Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Anlotinib (anlotinib)
• mXELIRI (mXELIRI)

Snippet

Sponsor: Guangzhou University of Traditional Chinese Medicine | Conditions: Advanced Colorectal Cancer | Phase 1, Phase 2 | Status: UNKNOWN